pular para conteúdo
Price indexes for clinical trial research : a feasibility study Ver prévia deste item
FecharVer prévia deste item
Checando...

Price indexes for clinical trial research : a feasibility study

Autor: Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
Editora: Cambridge, Mass. : National Bureau of Economic Research, 2013.
Séries: Working paper series (National Bureau of Economic Research), no. 18918.
Edição/Formato   e-book : Documento : InglêsVer todas as edições e formatos
Base de Dados:WorldCat
Resumo:
We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose  Ler mais...
Classificação:

(ainda não classificado) 0 com críticas - Seja o primeiro.

Assuntos
Mais como este

 

Encontrar uma cópia on-line

Encontrar uma cópia na biblioteca

&AllPage.SpinnerRetrieving; Encontrando bibliotecas que possuem este item...

Detalhes

Tipo de Material: Documento, Recurso Internet
Tipo de Documento: Recurso Internet, Arquivo de Computador
Todos os Autores / Contribuintes: Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
Número OCLC: 835500084
Notas: Title from http://www.nber.org/papers/18918 viewed April 4, 2013.
"March 2013."
Descrição: 1 online resource (35 p.) : ill.
Título da Série: Working paper series (National Bureau of Economic Research), no. 18918.
Responsabilidade: Ernst R. Berndt, Iain M. Cockburn.

Resumo:

We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services.

Críticas

Críticas contribuídas por usuários
Recuperando críticas GoodReas...
Recuperando comentários DOGObooks

Etiquetas

Seja o primeiro.
Confirmar esta solicitação

Você já pode ter solicitado este item. Por favor, selecione Ok se gostaria de proceder com esta solicitação de qualquer forma.

Dados Ligados


<http://www.worldcat.org/oclc/835500084>
library:oclcnum"835500084"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/835500084>
rdf:typeschema:Book
schema:about
<http://id.loc.gov/authorities/subjects/sh2007003908>
rdf:typeschema:Intangible
schema:name"Research and development projects--Costs--Econometric models."
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2013"
schema:description"We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1218425129>
schema:inLanguage"en"
schema:name"Price indexes for clinical trial research a feasibility study"
schema:publisher
schema:url
schema:url<http://www.nber.org/papers/w18918>

Content-negotiable representations

Close Window

Por favor, conecte-se ao WorldCat 

Não tem uma conta? Você pode facilmente criar uma conta gratuita.